Twist Bioscience had its Relative Strength (RS) Rating upgraded from 66 to 77 Friday — a welcome improvement, but still short of the 80 or better score you look for.
IBD's proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an 80 or better RS Rating as they begin their biggest climbs. See if Twist Bioscience can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Twist Bioscience is now considered extended and out of buy range after clearing a 43.21 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Twist Bioscience posted 0% EPS growth in the latest quarterly report, while sales growth came in at 24%.
Twist Bioscience earns the No. 115 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
